Compelling preclinical data in models of both GBA1-PD and idiopathic PD, demonstrating a disease-modifying effect after ...
WALTHAM, Mass., March 28, 2025 (GLOBE NEWSWIRE) -- Checkpoint Therapeutics, Inc. (“Checkpoint”) (Nasdaq: CKPT), a commercial-stage immunotherapy and targeted oncology company, today announced ...
Checkpoint Therapeutics, Inc. ("Checkpoint") (Nasdaq: CKPT), a commercial-stage immunotherapy and targeted oncology company, today announced financial ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback